menu
    • menu
    [{"orgOrder":0,"company":"BioAtla","sponsor":"Soleus Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Series D Financing","leadProduct":"CAB-AXL-ADC","moa":"AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"BioAtla \/ Soleus Capital","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Soleus Capital"},{"orgOrder":0,"company":"BioAtla","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"BA3071","moa":"CTLA-4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ BeiGene","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ BeiGene"},{"orgOrder":0,"company":"BioAtla","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"CAB-AXL-ADC","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"BioAtla \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ J.P. Morgan"},{"orgOrder":0,"company":"BioAtla","sponsor":"Acuta Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Mecbotamab Vedotin","moa":"AXL","graph1":"Oncology","graph2":"Phase II","graph3":"BioAtla","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"BioAtla \/ Acuta Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"BioAtla \/ Acuta Capital Partners"},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"BA3182","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Not Applicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BA3361","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAtla \/ Not Applicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Evalstotug","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BioAtla \/ Not Applicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ozuriftamab Vedotin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioAtla","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioAtla \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"BioAtla \/ Not Applicable"},{"orgOrder":0,"company":"BioAtla","sponsor":"Context Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"BA3362","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"BioAtla","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"BioAtla \/ Context Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"BioAtla \/ Context Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by BioAtla

    Menu

    BioAtla

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA3362

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Context Therapeutics

                            Deal Size : $133.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            BioAtla and Context Partner On BA3362 Antibody Therapy Development

                            Details : The context will obtain from BioAtla an exclusive, worldwide license to develop, manufacture, and commercialize BA3362, Nectin-4 x CD3 TCE for the treatment of neoplasms.

                            Brand Name : BA3362

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 23, 2024

                            Lead Product(s) : BA3362

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Context Therapeutics

                            Deal Size : $133.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ozuriftamab Vedotin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioAtla Receives FDA Fast Track Designation for Ozuriftamab Vedotin in Head & Neck Cancer

                            Details : The company's BA3021 (ozuriftamab vedotin), a conditionally and reversibly active antibody-drug conjugate targeting ROR2, is being evaluated for the treatment of SCCHN.

                            Brand Name : BA3021

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 23, 2024

                            Lead Product(s) : Ozuriftamab Vedotin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Evalstotug,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioAtla Presents Evalstotug Data at the 2024 ASCO Annual Meeting

                            Details : Phase 1 study is being conducted to evaluate BA3071 (evalstotug), an anti-CTLA-4 Conditionally Active Biologic, in combination with nivolumab in advanced solid tumors.

                            Brand Name : BA3071

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 23, 2024

                            Lead Product(s) : Evalstotug,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA3361

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioAtla Receives FDA Clearance for BA3361 Antibody Drug Conjugate

                            Details : BA3361, CAB-Nectin4-ADC, is an antibody-drug conjugate targeting Nectin4, currently evaluated for treating multiple tumor types, including pancreatic cancer.

                            Brand Name : BA3361

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 06, 2024

                            Lead Product(s) : BA3361

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA3182

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispec...

                            Details : BA3182 is a conditionally active biologic (CAB) EpCAM/CD3 bispecific T cell engager antibody. It is being developed as a potential anticancer therapy for patients with advanced adenocarcinoma.

                            Brand Name : BA3182

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 23, 2023

                            Lead Product(s) : BA3182

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mecbotamab Vedotin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Acuta Capital Partners

                            Deal Size : $65.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            BioAtla Announces $65 Million Underwritten Offering of its Common Stock

                            Details : BioAtla intends to use the net proceeds to fund research and development efforts, including Phase 2 clinical trials and potential commercialization of mecbotamab vedotin (BA3011), Phase 2 clinical trials of ozuriftamab vedotin (BA3021), clinical developm...

                            Brand Name : BA3011

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 03, 2022

                            Lead Product(s) : Mecbotamab Vedotin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Acuta Capital Partners

                            Deal Size : $65.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAB-AXL-ADC,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Solid Tumor Biotech Bio Atla Sets Terms for $150 Million IPO

                            Details : BioAtla has initiated Phase 2 trials for its two latest stage antibody-drug conjugate candidates BA3011 and BA3021 in multiple cancer indications, with interim data expected in 2021.

                            Brand Name : BA3011

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 09, 2020

                            Lead Product(s) : CAB-AXL-ADC,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA3071,Tislelizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BeiGene

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Bioatla and Beigene Revise Global Development and Commercialization Agreement

                            Details : Under the amended agreement, BeiGene will hold an exclusive global license to BA3071 and will be solely responsible for its global clinical development and commercialization and have the right to receive all profits on any future sales net of royalty pay...

                            Brand Name : BA3071

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 06, 2020

                            Lead Product(s) : BA3071,Tislelizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BeiGene

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAtla

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAB-AXL-ADC

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Soleus Capital

                            Deal Size : $72.5 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            BioAtla Rakes in $72.5M Series D, Advancing Research for pH-Detecting Cancer Treatments

                            Details : Funds will go toward company's four main clinical programs developing cancer treatments, two of which are currently in Phase II, BioAtla president and former Celgene COO Scott Smith said.

                            Brand Name : BA3011

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 16, 2020

                            Lead Product(s) : CAB-AXL-ADC

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Soleus Capital

                            Deal Size : $72.5 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth